Anti-phospho-JAK2 (Tyr1007/1008) Antibody

130 kDa

JAK2 (Janus Kinase 2) belongs to the emerging family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to CIS elements upstream of target gene promoters to regulate transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor. Among a variety of sites, Tyrosines 1007 and 1008 are sites of trans- or autophosphorylation in vivo and in in vitro kinase reactions.

Epitope: Tyr1007/1008

KLH-conjugated, synthetic peptide corresponding to amino acids surrounding phosphotyrosines 1007 and 1008 of human JAK2.

Anti-phospho-JAK2 (Tyr1007/1008) Antibody detects level of phospho-JAK2 (Tyr1007/1008) & has been published & validated for use in WB.

Research Category
Signaling

Research Sub Category
Immunological Signaling

Predicted to cross-react with rat based on sequence homology.

Recognizes phosphorylated JAK2, Mr 130 kDa.

Protein A purified

Format: Purified

Purified rabbit IgG in buffer containing 0.1M Tris-Glycine, 0.15M NaCl, 0.05% Sodium Azide, pH7.4.

Stable for 1 year at 2-8°C from date of receipt. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Control
Human ovarian cancer cells, GM-CSF-treated TF-1 cells.

Routinely evaluated by Western Blot on Pervanadate treated L6 lysates.

Western Blot Analysis:
1:500 dilution of this lot detected PHOS-JAK2 (TYR1007/1008) on 10 ug of Pervanadate treated L6 lysates.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Replaces: 04-1098

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.